# ADR 499 — Enterprise Biotechnology / Bio Intelligence Foundation (P217)

## Status

Accepted — **P217 Master Series Foundation**

## Context

P216 Master Series completed with robotics supreme nexus (ADR 498). P217 introduces the biological intelligence dimension of MEOS — AI + Quantum + Robotics + Biotechnology — as a new platform SoR, distinct from hospital EMR, laboratory LIMS, and pharmacy.

## Decision

1. Create SoR `biotechnology` with fabric `meos_bio_intelligence_fabric` at `/api/v1/biotechnology*`.
2. Capability `CAP-PLT-BIO-001`; eight BCs (biotechnology research through bio governance).
3. Core domain: Enterprise Biological Intelligence Management; aggregate BioIntelligenceAggregate.
4. Bio-AI via P214-Z ACL; quantum bio-compute via P215-Z ACL; lab robotics via P216-Z ACL.
5. Never replace hospital, laboratory, pharmacy, robotics, Core, AI, Quantum, or Identity.
6. Genomic privacy, ethical bioengineering, scientific reproducibility, and human-centered health intelligence are mandatory; opaque bio safety decisions forbidden.
7. External research institutions and scientific computing via Integration Platform.
8. Series continues with P217-A (mission/vision/scope & capability framework).

## Consequences

Positive: unified bio-intelligence platform under dedicated SoR with ethics and privacy gates.  
Negative: clinical systems remain peer SoRs; biotechnology projects health/LIMS data via ACL and events only.

## Alternatives rejected

- Sibling `bio_ai` / `synthetic_biology` / `digital_health` BCs outside SoR biotechnology.
- Extending `laboratory` or `hospital` with synthetic biology / bio-AI platform logic.
- Embedding OpenAI/vendor biology SDKs or clinical EMR engines in biotechnology domain.

## Related

Law: `ENTERPRISE_BIOTECHNOLOGY_FOUNDATION.md`  
Roadmap: `biotechnology/P217_MASTER_SERIES_ROADMAP.v1.yaml`
